Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Titel:
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Auteur:
Burris III, Howard A Flinn, Ian W Patel, Manish R Fenske, Timothy S Deng, Changchun Brander, Danielle M Gutierrez, Martin Essell, James H Kuhn, John G Miskin, Hari P Sportelli, Peter Weiss, Michael S Vakkalanka, Swaroop Savona, Michael R O'Connor, Owen A